INS and metabolic syndrome: In the unmatched original cohort, the values of standardized difference were >10% for age, dyslipidemia, obesity, nephropathy, eye diseases, insulin, meglitinide, acarbose, rosiglitazone, pioglitazone, statin, and fibrate, suggesting potential residual confounding from these variables.